|
|
|
|
 Dr Jeremy Barton,
Vice President Oncology R&D Biogen Idec Jeremy Barton, M.D. has 18 years experience in all phases of oncology drug development and commercialization activities in the pharmaceutical industry and has worked in Switzerland, the UK and the United States. Prior to joining Biogen Idec in July 2006, he held senior clinical research roles at Millennium, Elan, Glaxo Wellcome and Seattle Genetics as well as having his own consulting company. He currently is the Chief Medical Officer – Oncology at the Biogen Idec San Diego campus.
After obtaining a Masters Degree in Physiology at Oxford University and his M.D. degree at University College Hospital Medical School in London, he trained in Internal Medicine and Clinical Oncology in the United Kingdom and practiced for 11 years in the National Health Service.
Jeremy is Board Certified in Internal Medicine and Clinical Oncology, a Member of the Royal College of Physicians, a Fellow of the Royal College of Radiologists (Clinical Oncology) and a Member of Faculty of Pharmaceutical Medicine.
Appearing: DAY 3 THURSDAY 23 SEPTEMBER – CLINICAL TRIALS, COLLABORATIONS & COMBINATION THERAPY 10.10am Evaluating a Phase 1 trial and the criteria for viable progression into Phase 2 studies
- Comparative analysis of the success of Phase 1 trials and the impact on efficacy later down the line.
- How are the criteria for continuing development of a product into further clinical trials established and subsequently met?
- What are the implications of the information obtained from Phase 1 trials for the development of a marketable targeted oncology product
Dr Jeremy Barton, Vice President Oncology R&D,
Biogen Idec 3.30pm Extended panel discussion with Q&A: how is big pharma driving targeted cancer therapies to the forefront of the oncology industry?
- Scientifically – what are the areas of greatest potential for further development? Which industry profiles hold the key to developing them?
- Clinically – has the time come to readdress how oncology trials are planned and executed? What are the alternatives?
- Commercially – how can we integrate science and clinical outcomes into a successful business plan that meets the requirements of drug developers, patients, clinicians and government?
Dr Jeremy Barton, Vice President Oncology R&D,
Biogen Idec Senior Vice President R&D, Global Head Therapeutic Area Oncology,
Merck Serono Vice President Clinical Oncology,
Human Genome Sciences Global Brand Physician,
AstraZeneca Pharmaceuticals |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
